Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Return on Sales (2016 - 2025)

Adma Biologics' Return on Sales history spans 14 years, with the latest figure at 0.35% for Q4 2025.

  • For Q4 2025, Return on Sales fell 60.0% year-over-year to 0.35%; the TTM value through Dec 2025 reached 0.29%, down 18.0%, while the annual FY2025 figure was 0.29%, 18.0% down from the prior year.
  • Return on Sales reached 0.35% in Q4 2025 per ADMA's latest filing, up from 0.27% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.95% in Q4 2024 to a low of 1.14% in Q1 2021.
  • Average Return on Sales over 5 years is 0.1%, with a median of 0.04% recorded in 2023.
  • Peak YoY movement for Return on Sales: skyrocketed 116bps in 2021, then crashed -60bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 0.3% in 2021, then rose by 21bps to 0.24% in 2022, then surged by 161bps to 0.14% in 2023, then surged by 564bps to 0.95% in 2024, then crashed by -63bps to 0.35% in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Return on Sales are 0.35% (Q4 2025), 0.27% (Q3 2025), and 0.28% (Q2 2025).